Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:group_of_people
|
| gptkbp:condition |
gptkb:Amyotrophic_Lateral_Sclerosis
|
| gptkbp:hasMedianSurvival |
2 to 5 years after diagnosis
|
| https://www.w3.org/2000/01/rdf-schema#label |
North American ALS patients
|
| gptkbp:locatedIn |
gptkb:North_America
|
| gptkbp:mayReceiveSupport |
gptkb:ALS_Association
|
| gptkbp:mayReceiveTreatment |
gptkb:edaravone
gptkb:riluzole |
| gptkbp:mortalityRate |
high
|
| gptkbp:participatedIn |
ALS research studies
|
| gptkbp:prevalence |
about 5,000 new cases per year in the US
|
| gptkbp:receivesCareFrom |
neurologists
|
| gptkbp:riskFactor |
age
genetic predisposition environmental factors |
| gptkbp:studiedIn |
ALS clinical trials
|
| gptkbp:symptom |
difficulty speaking
difficulty swallowing muscle weakness muscle cramps respiratory difficulties |
| gptkbp:bfsParent |
gptkb:A4V
|
| gptkbp:bfsLayer |
6
|